Encompass Pharmaceutical Services Inc, Norcross, GA, USA.
J Drug Target. 2012 May;20(4):364-71. doi: 10.3109/1061186X.2012.662686. Epub 2012 Feb 18.
The role of albumin-based chitosan microparticles on enhancing immune response of plasmid DNA (pDNA) to hepatitis-B surface antigen (HBsAg) vaccine after oral administration was investigated in mice. The pDNA encoding HBsAg was entrapped in albumin microparticles using a one-step spray drying technique optimized in our laboratory. The encapsulated particles were also characterized in vitro for their shape, size, encapsulation efficiency, content, and stability. Albumin microparticles could protect the DNA from nuclease degradation as confirmed in our agarose gel study. Further immune modulating effect was studied in our formulation by measuring IgG antibodies in serum as well as IgA antibodies in fecal extracts. The mice were immunized with a prime dose of 100 μg of pDNA in microparticle formulations with and without interleukins biweekly until week 7 followed by a booster dose of equivalent strength on week 33 to compare the response with the subcutaneous group. The oral immunization with the pDNA to HBsAg microparticles gave significantly higher titer level of both sIgA and IgG at week 9 and 34, respectively, in oral vaccine with interleukins group when compared with the subcutaneous group. Thus, we observed an augmentation of both humoral and cellular immune responses for prolonged periods after immunization.
研究了基于白蛋白的壳聚糖微球在口服乙型肝炎表面抗原(HBsAg)疫苗后增强质粒 DNA(pDNA)免疫反应的作用。使用我们实验室优化的一步喷雾干燥技术,将编码 HBsAg 的 pDNA 包封在白蛋白微球中。还对包封的颗粒进行了体外特性研究,包括形状、大小、包封效率、含量和稳定性。琼脂糖凝胶研究证实,白蛋白微球可以保护 DNA 免受核酸酶降解。通过测量血清中的 IgG 抗体和粪便提取物中的 IgA 抗体,进一步研究了我们配方中的免疫调节作用。用 100 μg 的 pDNA 作为初免剂量,每周两次免疫微球制剂,直到第 7 周,然后在第 33 周加强相同剂量,与皮下组进行比较。与皮下组相比,用白细胞介素的 pDNA 至 HBsAg 微球口服免疫在第 9 周和第 34 周分别显著提高了 sIgA 和 IgG 的滴度水平。因此,我们观察到免疫后长时间内体液和细胞免疫反应增强。